Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 8/20 | 0.56 |
| ▸ | BRD4 | O60885 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15980791 | 0.84 | BRD4 (0.51) | NR4A2BRD4KMT2APARP1LMNA | |
| SCHEMBL23809344 | 0.84 | NOTUM (0.40) | BRD4KMT2AKDM4ELMNAALDH1A1 | |
| SCHEMBL26581229 | 0.81 | NR4A2 (0.60) | NR4A2BRD4KMT2AMEN1PARP1 | |
| SCHEMBL17113153 | 0.79 | NR4A2 (0.59) | NR4A2BRD4KMT2AMEN1PARP1 | |
| SCHEMBL3285149 | 0.78 | NR4A2 (0.57) | NR4A2BRD4KMT2AMEN1PARP1 | |
| SCHEMBL31022913 | 0.78 | NR4A2 (0.43) | NR4A2BRD4KMT2AMEN1LMNA | |
| SCHEMBL20738337 | 0.75 | KDM4E (0.49) | NR4A2BRD4KMT2AKDM4ELMNA | |
| SCHEMBL18999663 | 0.74 | GABRA1 (0.40) | KMT2AMEN1LMNAALDH1A1MAPT | |
| SCHEMBL7791811 | 0.73 | KDM4E (0.50) | KMT2AKDM4ELMNAALDH1A1MAPT | |
| SCHEMBL29217699 | 0.73 | NR4A2 (0.45) | NR4A2BRD4KMT2AMEN1PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | NR4A2 2684/4885BRD4 71/4885KMT2A 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.